

PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER, NO. CHM-003 10/551,105 V Jeffrey A. Whitsett INTERNATIONAL APPLICATION NO. PCT/US04/09264 I.A. FILING DATE PRIORITY DATE 38155 03/27/2003 03/26/2004

HASSE & NESBITT LLC 7550 CENTRAL PARK BLVD., MASON, OH 45040

CONFIRMATION NO. 4312 371 FORMALITIES LETTER

OC000000019402843

Date Mailed: 06/28/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8. 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8. 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(b), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading anc include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

FREDERICK SMITH

Telephone: (703) 308-9140 EXT 210

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
O.S. ALI EICATION NOMBERNO.		



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, 'Alexandria, VA 22313-1450 on August 28, 2006.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/551,105

Confirmation No.: 4312

Filed:

March 26, 2004

Group Art Unit:

1645

Examiner:

Unknown

Applicant:

Jeffrey A. Whitsett

Title:

USE OF FGF-18 PROTEIN, TARGET PROTEINS AND THEIR

RESPECTIVE ENCODING NUCLEOTIDE SEQUENCES TO INDUCE

CARTILAGE FORMATION

Attorney Ref:

CHM-003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 August 28, 2006

Sir:

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

In response to the Notification to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, please find enclosed herewith a copy of such Notice along with the following as it pertains to the sequence listing originally filed:

Applicant hereby states that the content of the sequence listing information recorded in computer readable form is identical to the written (paper copy) sequence listing, and contains no new matter.

No fees are required with this response.

Respectfully submitted, For JEFFREY A. WHITSETT, MD

By:

Ronald J. Richter, Reg. No. 52,408

HASSE & NESBITT, LLC Customer Number: 38155

(513) 229-0383 (voice) (513) 229-0683 (facsimile)

-2-